Oncology Biosimilars Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Oncology Biosimilars Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028


Market Overview:

The global oncology biosimilars market size reached US$ 3.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 14.7 Billion by 2028, exhibiting a growth rate (CAGR) of 21.6% during 2023-2028.

Cancer is a lifestyle disease that occurs due to the abnormal growth of cells and may result in the formation of a tumor. At present, most of the effective cancer treatments are based on biological drugs, also known as biologics, and include targeted therapies as well as immunotherapies. These drugs are produced using living organisms, including bacteria, yeast, and animal or plant cells, and require complex manufacturing processes and long development time. As a result, the cost of these drugs is relatively higher, which adds to the expense of cancer treatment. To lower the price of treatment, the interest in the development of biosimilars of branded oncology biologics has been increasing. These biosimilars are highly similar to the reference biologics in terms of effectiveness and safety and can help in significantly reducing the expenditure on cancer treatment due to their lower cost.

Over the years, the rising number of geriatric population and environmental degradation have increased the prevalence of cancer across the globe. These factors, along with the inflating cost of cancer care, have increased the burden on healthcare systems worldwide. Consequently, governing authorities in numerous countries are promoting the uptake of biosimilars as a cost-containment measure. For instance, the United States Food and Drug Administration (USFDA) has developed information materials for physicians and patients to educate them about biosimilars. Apart from this, the availability of affordable medication has also been associated with earlier and wider therapy use as well as improved patient access. Besides this, oncology biosimilars can also increase industry competition, owing to which they have the potential to drive down the prices of biological drugs further. Some of the other growth-inducing factors for the market include approaching patent expiries of branded biologics and increasing research and development (R&D) activities by biosimilar manufacturers.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global oncology biosimilars market report, along with forecasts at the global and regional level from 2023-2028. Our report has categorized the market based on drug type, cancer type and distribution channel.

Breakup by Drug Type:

Monoclonal Antibody
Immunomodulators
G-CSF
Hematopoietic Agents
Others

Breakup by Cancer Type:

Lung Cancer
Colorectal Cancer
Cervical Cancer
Breast Cancer
Kidney Cancer
Stomach Cancer
Brain Cancer
Others

Breakup by Distribution Channel:

Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Others

Breakup by Region:

Europe
Asia Pacific
North America
Middle East and Africa
Latin America
Competitive Landscape:
The report has also analyzed the competitive landscape of the market with some of the key players being Biocon Limited, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD Biotechnology Company, Mylan N.V., F. Hoffmann-La Roche AG, etc.

Key Questions Answered in This Report:
How has the global oncology biosimilars market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global oncology biosimilars industry?
What are the key regional markets in the global oncology biosimilars industry?
What is the breakup of the market based on the drug type?
What is the breakup of the market based on the cancer type?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the global oncology biosimilars industry?
What are the key driving factors and challenges in the global oncology biosimilars industry?
What is the structure of the global oncology biosimilars industry and who are the key players?
What is the degree of competition in the global oncology biosimilars industry?


1 Preface
2 Scope and Methodology
2.1Objectives of the Study
2.2Stakeholders
2.3Data Sources
2.3.1Primary Sources
2.3.2Secondary Sources
2.4Market Estimation
2.4.1Bottom-Up Approach
2.4.2Top-Down Approach
2.5Forecasting Methodology
3 Executive Summary
4 Introduction
4.1Overview
4.2Key Industry Trends
5 Global Oncology Biosimilars Market
5.1Market Overview
5.2Market Performance
5.3Impact of COVID-19
5.4Market Breakup by Drug Type
5.5Market Breakup by Cancer Type
5.6Market Breakup by Distribution Channel
5.7Market Breakup by Region
5.8Market Forecast
6 Market Breakup by Drug Type
6.1Monoclonal Antibody
6.1.1Market Trends
6.1.2Market Forecast
6.2Immunomodulators
6.2.1Market Trends
6.2.2Market Forecast
6.3G-CSF
6.3.1Market Trends
6.3.2Market Forecast
6.4Hematopoietic Agents
6.4.1Market Trends
6.4.2Market Forecast
6.5Others
6.5.1Market Trends
6.5.2Market Forecast
7 Market Breakup by Cancer Type
7.1Lung Cancer
7.1.1Market Trends
7.1.2Market Forecast
7.2Colorectal Cancer
7.2.1Market Trends
7.2.2Market Forecast
7.3Cervical Cancer
7.3.1Market Trends
7.3.2Market Forecast
7.4Breast Cancer
7.4.1Market Trends
7.4.2Market Forecast
7.5Kidney Cancer
7.5.1Market Trends
7.5.2Market Forecast
7.6Stomach Cancer
7.6.1Market Trends
7.6.2Market Forecast
7.7Brain Cancer
7.7.1Market Trends
7.7.2Market Forecast
7.8Others
7.8.1Market Trends
7.8.2Market Forecast
8 Market Breakup by Distribution Channel
8.1Hospital Pharmacies
8.1.1Market Trends
8.1.2Market Forecast
8.2Online Pharmacies
8.2.1Market Trends
8.2.2Market Forecast
8.3Retail Pharmacies
8.3.1Market Trends
8.3.2Market Forecast
8.4Others
8.4.1Market Trends
8.4.2Market Forecast
9 Market Breakup by Region
9.1Europe
9.1.1Market Trends
9.1.2Market Forecast
9.2Asia Pacific
9.2.1Market Trends
9.2.2Market Forecast
9.3North America
9.3.1Market Trends
9.3.2Market Forecast
9.4Middle East and Africa
9.4.1Market Trends
9.4.2Market Forecast
9.5Latin America
9.5.1Market Trends
9.5.2Market Forecast
10 SWOT Analysis
10.1Overview
10.2Strengths
10.3Weaknesses
10.4Opportunities
10.5Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1Overview
12.2Bargaining Power of Buyers
12.3Bargaining Power of Suppliers
12.4Degree of Competition
12.5Threat of New Entrants
12.6Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1Market Structure
14.2Key Players
14.3Profiles of Key Players
14.3.1Biocon Limited
14.3.2Celltrion Inc.
14.3.3Dr. Reddy's Laboratories Ltd.
14.3.4Intas Pharmaceuticals Ltd.
14.3.5STADA Arzneimittel AG
14.3.6Pfizer Inc.
14.3.7Apotex Inc.
14.3.8Teva Pharmaceutical Industries Ltd.
14.3.9Sandoz International GmbH
14.3.10 BIOCAD Biotechnology Company
14.3.11 Mylan N.V.
14.3.12 F. Hoffmann-La Roche AG

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings